Comment to: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study-determination of immunogenicity.

Lenders, Malte; Brand, Eva

Lenders, Malte; Brand, Eva.

Affiliation

Lenders M; Internal Medicine D, Department of Nephrology, Hypertension and Rheumatology, University Hospital Münster, Münster, Germany malte.lenders@ukmuenster.de.
Brand E; Internal Medicine D, Department of Nephrology, Hypertension and Rheumatology, University Hospital Münster, Münster, Germany.

J Med Genet ; 61(6): 531-533, 2024 May 21.

Article de En | MEDLINE | ID: mdl-38538083

Sujet(s)
Mots clés

Antigenic Variation; Fabry Disease; alpha-Galactosidase

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Maladie de Fabry / Alpha-Galactosidase / Isoenzymes Limites: Humans Langue: En Journal: J Med Genet Année: 2024 Type de document: Article Pays d'affiliation: Allemagne

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google